Overview

To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Status:
COMPLETED

Trial end date:
2023-02-24

Target enrollment:

Participant gender:

Summary

The main objective of the study will be to assess the efficacy and safety of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) in patients with mild to moderate essential hypertension uncontrolled after 4-week treatment with Amlodipine besylate（5 mg) or Allisartan Isoproxil (240 mg).

Phase:

PHASE3

Details

Lead Sponsor:

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Treatments:

allisartan isoproxil